Company / Shareholders' Equity
Eloxx Pharmaceuticals, Inc. Shareholders' Equity History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$10.7M
FY2025
5-year range
-$10.7M / $27.5M
FY2021-FY2025
Trend
-138.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Eloxx Pharmaceuticals, Inc. reports negative total equity of -$11M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$11M in FY2025.
Declined from $4M to -$11M over the past 10 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 138.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -40.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$10.7M | -138.8% |
| FY2016 | $27.5M | +626.1% |
| FY2015 | $3.8M | +9.6% |
| FY2014 | $3.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026